Catherine Fedorenko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5495976/publications.pdf

Version: 2024-02-01

1307366 996849 16 802 15 7 citations g-index h-index papers 19 19 19 1264 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis. Health Affairs, 2013, 32, 1143-1152.	2.5	553
2	Characterizing Potentially Preventable Cancer- and Chronic Disease–Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. Journal of Oncology Practice, 2018, 14, e176-e185.	2.5	74
3	The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. Oncologist, 2016, 21, 320-326.	1.9	59
4	Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. Journal of Oncology Practice, 2015, 11, 338-343.	2.5	27
5	Risk of Adverse Financial Events in Patients With Cancer: Evidence From a Novel Linkage Between Cancer Registry and Credit Records. Journal of Clinical Oncology, 2022, 40, 884-891.	0.8	18
6	End-of-Life Services Among Patients With Cancer: Evidence From Cancer Registry Records Linked With Commercial Health Insurance Claims. Journal of Oncology Practice, 2017, 13, e889-e899.	2.5	17
7	Novel Data Linkages to Characterize Palliative and End-Of-Life Care: Challenges and Considerations. Journal of Pain and Symptom Management, 2019, 58, 851-856.	0.6	14
8	Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries. PLoS ONE, 2019, 14, e0222904.	1.1	8
9	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre-Versus Postimmune Checkpoint Inhibitor Eras. JCO Oncology Practice, 2021, 17, e1728-e1737.	1.4	7
10	Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non–small-cell Lung Cancer Treated in the Real-World. Clinical Lung Cancer, 2021, 22, e723-e733.	1.1	7
11	Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer, 2020, 6, e18143.	0.9	5
12	Clinical Characteristics, Treatment Patterns, and Healthcare Costs and Utilization for Hepatocellular Carcinoma (HCC) Patients Treated at a Large Referral Center in Washington State 2007–2018. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1597-1606.	1.8	5
13	Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database. JCO Oncology Practice, 2022, 18, e877-e885.	1.4	4
14	Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. Journal of Oncology Practice, 2018, 14, e801-e814.	2.5	3
15	Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. Journal of Racial and Ethnic Health Disparities, 2020, 7, 967-974.	1.8	1
16	Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer, 2020, 6, e23821.	0.9	0